Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again

Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again

Source: 
Xconomy
snippet: 

Sarepta Therapeutics won one of the most controversial drug approvals in recent memory, when the FDA in September 2016 approved the Duchenne muscular dystrophy drug eteplirsen (Exondys 51) off a slim set of data. The Cambridge, MA, company isn’t having the same luck in Europe.